ArticleJournal of family medicine and primary care2025
Assessing antimicrobial utilization and costs, and correlating biological markers with adverse events in ICU patients: An effort towards antimicrobial stewardship.
Article in Journal of family medicine and primary care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antimicrobials can worsen redox and inflammatory imbalances, leading to adverse drug events (ADEs). No comprehensive analysis of ADEs across antimicrobial classes with biological markers has been done in India. This study aimed to assess antimicrobial use patterns, costs, and ADEs among ICU patients and to explore the relationship between oxidative stress and inflammatory biomarkers and ADEs from antimicrobial therapy. Methods: Over 2 years at a tertiary hospital, 303 ICU patients on systemic antimicrobials for over 24 hours were studied. ADEs were documented until discharge. Antimicrobial use was assessed with the ATC classification and expressed as defined daily doses per 100 bed days. ADE causality and severity were evaluated with Naranjo's and Hartwig-Siegel scales. Correlations with oxidative stress (MDA, GSH, Nrf-2, 8-isoprostane, ADMA) and inflammatory biomarkers (IL-6, IL-10, hsCRP) were also analyzed. Results: A total of 739 antimicrobials were administered, averaging 2.4 per patient. Most were for infections (86.46%), with empirical therapy common (55.44%). Cultures showed no growth in 76.73% and bacterial growth in 20.86%, primarily respiratory infections (41.91%). Piperacillin-Tazobactam was the most used fixed-dose combination (14.9% of prescriptions), costing 720,273 INR (8783.80 USD). The total antimicrobial cost was 2,524,311 INR (30,784.30 USD). Eight mild to moderate ADEs (2.64%) were observed. IL-6 and hsCRP positively correlated with ADEs, while IL-10 negatively correlated. Oxidative stress markers MDA, ADMA, and 8-isoprostane were positively correlated with ADEs, while GSH and Nrf-2 were negatively correlated. Conclusion: The study underscores the need for antimicrobial stewardship and reveals significant correlations between biomarkers and ADEs, suggesting new prevention and management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.